Predicting relapse in chronic spontaneous urticaria: A retrospective cohort study evaluating omalizumab withdrawal regimens

Documenti analoghi

• Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria
  di: L. Zubiaga‐Fernandez, et al.
  Pubblicazione: (2024)
• Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study
  di: Guillaume Pierrard, et al.
  Pubblicazione: (2024)
• Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria
  di: Canan Caka, et al.
  Pubblicazione: (2025)
• Plasma proteomics analysis of patients with chronic spontaneous urticaria reveals significant associations with key disease characteristics but not with response to omalizumab treatment
  di: Misbah Noshela Ghazanfar, et al.
  Pubblicazione: (2024)
• Efficacy and safety of CT‐P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16‐week follow‐up study
  di: Clive Grattan, et al.
  Pubblicazione: (2025)